Changeflow GovPing Healthcare USPTO Letter to FDA CDER
Routine Notice Added Final

USPTO Letter to FDA CDER

Favicon for www.regulations.gov Regs.gov: Food and Drug Administration
Detected March 26th, 2026
Email

Summary

The U.S. Patent and Trademark Office (USPTO) has sent a letter to the FDA's Center for Drug Evaluation and Research (CDER). The document is available on Regs.gov, but no content or specific details of the letter's subject matter are provided.

View original document View source feed page

What changed

This entry pertains to a letter sent from the U.S. Patent and Trademark Office (USPTO) to the FDA's Center for Drug Evaluation and Research (CDER), posted on March 25, 2026. However, the document itself is unavailable for viewing or download on Regs.gov, and no further details regarding its content or purpose are provided.

As no specific regulatory changes, obligations, or deadlines are detailed, compliance officers do not need to take immediate action. The nature of the communication between these two agencies is unclear from the available metadata.

Source document (simplified)

Content

There are no documents available to view or download

Attachments 1

Letter from U.S Patent and Trademark Office to FDA CDER

More Information
- Author(s) CDER
Download

Related changes

Favicon for www.regulations.gov FDA Complaint Posted
Routine Mar 26, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov FDA Complaint Filed
Routine Mar 26, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov FDA Complaint Posted
Routine Mar 26, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.federalregister.gov DEA: SpecGx LLC Controlled Substances Manufacturer Application
Priority review Mar 26, 2026 • FR: Drug Enforcement Administration • Courts & Legal
Favicon for pharmacy.iowa.gov Iowa Board of Pharmacy Newsletter: Rule Delays, MPJE Update, New Board Members
Priority review Mar 26, 2026 • IA Board of Pharmacy News • Pharma & Drug Safety
Favicon for pharmacy.iowa.gov Iowa Board of Pharmacy Adopts UMPJE Exam, Updates PMP Access
Priority review Mar 26, 2026 • IA Board of Pharmacy News • Pharma & Drug Safety

Source

Favicon for www.regulations.gov
Regs.gov: Food and Drug Administration regulations.gov/search?agencyIds=FDA&sortBy=postedDate&sortDirection=desc
Healthcare
Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
FDA
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2025-E-6103-0004

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property

Browse Categories

Agriculture & Food Safety 62 AI Regulation 3 Banking & Finance 240 Consumer Protection 41 Courts & Legal 322 Data Privacy & Cybersecurity 65 Defense & National Security 49 Education 20 Energy 105 Environment 84 Government & Legislation 264 Healthcare 133 Housing 16 Immigration 9 Insurance 56 Labor & Employment 111 Legal & Courts 1 Pharma & Drug Safety 101 Securities & Markets 81 Tax 64 Telecom & Technology 48 Trade & Sanctions 124 Transportation 56

Get Healthcare alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.